PTEN (phosphatase and tensin homolog deleted on chromosome 10) tumor suppressor regulates a variety of cellular processes including cell proliferation, growth, migration and death. This master regulator itself is also under deliberative regulation. Although the evidence for PTEN regulation and its significance in normal biology and disease is overwhelming, the mechanisms and exact functional consequences of PTEN regulation are far from clear. In this review, we discuss recent advances concerning post-translational regulation of PTEN in general, and in more detail about its regulation by ubiquitination. We also discuss some unsolved questions in the field and how they might be addressed in the future. We propose that the complex regulatory mechanisms of PTEN dictate how this tumor suppressor executes its distinct biological functions.
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PTEN as a multifunctional biological regulator
Ever since the original discovery of the PTEN (phosphatase and tensin homolog deleted on chromosome 10) gene independently by laboratories of Parsons (Li et al., 1997) and Steck (Steck et al., 1997) , this important tumor suppressor continues to generate new excitement and surprises for the research community. An early breakthrough is the discovery of its unsuspected biochemical nature as a phosphatase for the lipid second messenger phosphatidylinositol-3,4,5-triphosphate (PIP3) (Maehama and Dixon, 1998) . A more recent excitement is the identification of additional novel and complicated biological roles of PTEN using elegant mouse genetic approaches. For example, it was reported that PTEN is required for the maintenance of hematopoietic stem cell populations while inhibiting blood cancer stem cells, suggesting that the enhancing/restoring PTEN function might be a promising therapeutic approach to combat blood cancer stem cells without eliminating normal blood stem cells (Yilmaz et al., 2006; Zhang et al., 2006) . Additionally, PTEN was shown to control ovarian follicle activation and therefore reproduction of mammals (Reddy et al., 2008) . The roles of PTEN in the development and function of specific organs/tissues, such as brain, heart, and bone, have also been reported (Backman et al., 2001; Groszer et al., 2001; Kwon et al., 2001 Kwon et al., , 2006 Crackower et al., 2002; Liu et al., 2007; Oudit et al., 2008) .
On the other hand, it appears that all these diverse biological functions and tumor-suppressive capabilities of PTEN can be explained by its single biochemical activity, that is, by dephosphorylating the lipid second messenger PIP3, PTEN negatively regulates the phosphoinositide-3 kinase (PI3K)-Akt signaling pathway, and thereby affects multiple downstream events, including cell growth, metabolism, proliferation and survival. The strong evidence for this argument is that many physiological abnormalities and tumorigenesis caused by the loss of PTEN function are associated with Akt activation and can be attenuated by pharmacological inhibition of PI3K, Akt or downstream components such as, mammalian Target of Rapamycin (mTOR) (Backman et al., 2001; Groszer et al., 2001; Kwon et al., 2001 Kwon et al., , 2006 Crackower et al., 2002; Liu et al., 2007; Oudit et al., 2008) .
This scenario had been thought to be even simpler. An early opinion in the field was that PTEN functioned not only strictly as a negative component of PI3K-Akt signaling but also rather passively as a blocker or fine tuner of the kinase cascade. Indeed, versatile and sophisticated regulation of other components of the PI3K-Akt pathway renders any direct regulation of PTEN function seemingly unnecessary. For example, there are multiple classes of PI3K, which are composed of different catalytic subunits and regulatory subunits. These PI3K molecules mediate distinctive signals transduced through their correspondent tyrosine kinase receptors or G-protein-coupled receptors, thus provide multiple levels of regulation. Furthermore, some isoforms of PI3K are only expressed in selective tissues, providing tissue-specific regulatory mechanism (for a recent review, see Engelman et al., 2006) . In addition, downstream of PTEN, the essential kinase Akt, is also regulated by multiple mechanisms; the existence of three isoforms of Akt further diversifies the possible routes of modulation (Brognard et al., 2007; Dummler and Hemmings, 2007) . In contrast, PTEN functions to eliminate the common moiety of the pathway, PIP3, thus it alone cannot distinguish individual signals from distinct PI3K isoforms to various Akt isoforms. For this reason, PTEN appears to be a rather poor and unnecessary choice for specific regulation.
Yet, the function and regulation of PTEN has turned out to be much more complex. First, it has now been firmly established that PTEN also possesses multiple biological functions independent of its lipid phosphatase activity. These include regulation of cell migration, cell cycle transition and, recently reported, chromosomal integrity (Tamura et al., 1998; Hlobilkova et al., 2000; Weng et al., 2001; Raftopoulou et al., 2004; Shen et al., 2007) . PTEN exerts such functions by protein-protein interaction or by its protein phosphatase activity. To study these 'non-canonical' functions, it is crucial to generate a series of mouse models such as mutant Ptenknockin mice (for example, G129E to inactivate the lipid but not protein phosphatase activity, and C124S to inactivate both enzymatic activities), preferentially in a conditional manner to achieve developmental and tissue specificity. Secondly, much against the earlier thought that PTEN regulation was not necessary, mounting evidence shows that PTEN is under deliberate regulation. It is probably these complex regulatory mechanisms that dictate the versatile cellular and biological functions of the tumor suppressor. Currently, the field is only beginning to grasp the molecular basis of multiple fashions of PTEN regulation and the subsequent biological effects.
PTEN regulation revealed by basic and cancer research
The fact that PTEN is closely regulated in cells was established based on two lines of intertwined research, cancer-oriented research and basic research of this tumor suppressor. PTEN can be regulated both transcriptionally and post-translationally, but this review will only focus on the latter.
Cancer research
Following identification of the PTEN gene, multiple mouse genetic studies confirmed that PTEN is a potent tumor suppressor (Di Cristofano et al., 1998; Stambolic et al., 1998; Podsypanina et al., 1999) . More recently, an elegant mouse prostate tumor study by Pandolfi and colleagues showed that the Pten expression level correlates inversely in a dose-dependent manner with prostate cancer initiation, latency, progression and changes in the PI3K-Akt pathway (Trotman et al., 2003) . On the basis of this result, it is logically possible that in addition to direct genetic mutation/deletion of PTEN, attenuation of PTEN function caused by perturbation of its post-translational regulation could also be a significant contributor for cancer development. The obvious biological effect caused by a modest change of Pten expression level also emphasizes that Pten function needs to be precisely controlled in a temporally and spatially specific manner. PTEN cancer research also generated multiple lines of solid evidence supporting the presence of regulatory mechanisms for PTEN function. PTEN gene transcription can be dramatically decreased in human cancer due to silencing of its promoter by DNA methylation (Whang et al., 1998; Mirmohammadsadegh et al., 2006; Wiencke et al., 2007) . Additionally, certain cancer samples with wild-type PTEN gene have undetectable/ low levels of PTEN protein (Perren et al., 1999; Wang et al., 2007) , possibly due to abnormal post-translational regulation of PTEN, such as that of PTEN protein degradation. Consistently, multiple cancer-derived PTEN mutations cause a decrease in PTEN protein stability in cells (Georgescu et al., , 2000 . Speculatively, the malfunction of post-translational regulation might also be able to ablate the enzymatic activity of PTEN even in human cancers with unmutated PTEN protein expressed at the normal level. This possibility is supported by the observation that in some human melanoma samples with wild-type PTEN protein expressed at normal level, the phospho-Akt level is nevertheless quite high.
PTEN cancer research also revealed a novel tumorsuppressive function of PTEN in the nucleus and thus potential regulation of PTEN nuclear import. Eng and colleagues originally observed that a significant population of PTEN is nuclear-localized in multiple human tissues; importantly, loss of this nuclear PTEN population correlated with cancer development (Gimm et al., 2000; Whiteman et al., 2002) . This observation had been somewhat neglected for long time until recently when the presence and novel tumor-suppressive function of nuclear PTEN were extensively documented (we will discuss nuclear PTEN in a later session).
Basic research
The original experiments that defined the lipid phosphatase activity of PTEN immediately suggested that PTEN activity should be regulated post-translationally. In this seminal work (Maehama and Dixon, 1998) , Dixon and colleagues showed that when cells were treated with insulin, overexpression of the catalytically inactive PTEN mutant (C124S) resulted in a further increase of PIP3 levels. This and other results not only demonstrated that PTEN is a phosphatase for PIP3 but also revealed a dominant-negative effect of the inactive PTEN mutant. How can the PTEN mutant be dominant-negative? Competition for the substrate PIP3 with the endogenous wild-type PTEN cannot be the reason considering the excessive amount of PIP3, a lipid small molecule, over PTEN, a rather low-abundant signaling protein in cells. Thus, it is only possible that the overexpressed PTEN mutant competes with the endogenous PTEN for certain regulatory/stimulatory factor(s). In other words, endogenous PTEN activity to dephosphorylate PIP3 is post-translationally regulated by additional components.
In addition, the fact that PTEN is predominantly cytosolic in most cell types yet its substrate PIP3 is at plasma membrane suggests that its cellular localization needs to be regulated. PTEN membrane targeting is transient and dynamic based on experimental observations (Vazquez et al., 2006) , and understanding of the molecular basis underlying PTEN membrane targeting is still limited. PTEN possesses a C2 domain and an N-terminal PIP2-binding motif, which are involved in PTEN membrane targeting and thus critical for the cellular PIP3 phosphatase activity of the enzyme (Lee et al., 1999; Walker et al., 2004) . Localization of PTEN to the plasma membrane by these domains is presumably influenced by the local PIP2 and PIP3 concentrations (Iijima et al., 2004) , which in turn are controlled by PI3 kinase activity in the upstream of PTEN signaling. Importantly, PTEN can also be recruited to special plasma membrane locations via protein-protein interaction. For example, NHEFR (Na þ /H þ exchanger regulatory factor) proteins, which interact with plateletderived growth factor (PDGF) receptors, recruit PTEN to the plasma membrane to specifically attenuate PDGF signaling (Takahashi et al., 2006) . Conceptually, this function of NHEFR might have significant implications. First, it represents an efficient mechanism to localize PTEN to specific plasma membrane sites where its activity is needed. Second, it suggests that only a small percent of total cellular PTEN is involved in (and sufficient for) antagonizing PDGF-Akt signaling, which might be the main reason why the majority of cellular PTEN is always cytosolic in many types of cells. Third, such a regulatory mechanism might be common for PTEN to be recruited to defined plasma membrane locations upon sensing specific signals (it can certainly explain why the overexpression of inactive PTEN mutant is dominant-negative upon insulin stimulation; Maehama and Dixon, 1998) . Thus, coupled with additional regulatory components, PTEN can control distinctive signaling pathways in a highly effective and specific manner, although it acts on the common and indistinguishable moiety, PIP3, of various pathways.
Therefore, on the basis of early basic and canceroriented PTEN research, it is clear that three general properties of cellular PTEN, expression level (protein stability), subcellular localization and intrinsic enzymatic activity, can all be subjected to post-translational regulation. In the later part of this review, we will try to dissect the impact of the different regulatory mechanisms on these three closely connected properties.
Two general mechanisms for PTEN post-translational regulation
Protein-protein interaction It has been reported that PTEN can interact with many proteins, such as MAGI-2 (Tolkacheva et al., 2001) , PICT-1 (Okahara et al., 2004) , MSP58 (Okumura et al., 2005) , the microtubule-associated serine/threonine kinases MAST-1 and MAST-3 (Valiente et al., 2005) , the nuclear histone acetyltransferase P300/CBP-associated factor (PCAF) (Okumura et al., 2006) and NHERF proteins (Takahashi et al., 2006) . Most of these proteins interact with the C-terminal PDZ binding motif of PTEN. Although the physiological relevance of many of these interactions needs to be validated, it is possible that some of these associating proteins can regulate PTEN function including its enzymatic activity; conversely, it is also likely that PTEN regulates the function of its binding partners. However, these possibilities have not been rigorously examined for most of the PTEN associating proteins.
A straightforward approach to address this issue is simply to reconstitute the biochemical interaction in vitro, and then to examine the effect of the interaction on the enzymatic activity of PTEN or vice versa. It should be noted that PTEN is a phosphatase for both the phospholipid PIP3 and yet-to-be-defined phosphoprotein(s). These dual functions might be differentially regulated, and thus both need to be examined. Synthetic phospho-peptides can be used as substrates to measure protein phosphatase activity of PTEN. For measuring PIP3 phosphatase activity, instead of the commonly used water-soluble synthetic short chain PIP3, natural PIP3 in plasma membrane-mimicking liposomes is highly suggested to be used as the substrate, because the plasma membrane per se probably is an important component in the regulation of the PIP3 phosphatase activity of PTEN. The same in vitro reconstituted system can also be used to test the other direction of the equation: potential regulation of the associated factors by PTEN, that is, novel functions of PTEN. Such experiment is particularly feasible for PCAF, MAST-1, and MAST-3, because of their biochemical nature as enzymes.
This in vitro biochemical approach has its own limitations. First, it is possible that the interaction of PTEN with an associating protein requires specific stimulation, for example, an induced post-translational modification on either PTEN or the binding protein. For such cases, a more detailed understanding of the interaction is needed before the in vitro analysis can be performed. Secondly, some PTEN binding proteins might simply act as an adaptor protein to guide PTEN to specific cellular compartments and subsequently to function there. These associating factors might have no direct effect on the enzymatic activity of PTEN and thus their function cannot be addressed by the in vitro approach (membrane targeting proteins are exceptions). Thirdly, the interaction might regulate the protein stability of PTEN: such an effect will also evade the in vitro reconstituted system that focuses only on enzymatic activity.
When the in vitro assay identifies a potential effect of the interaction on either PTEN or the binding partner, the cellular relevance needs to be carefully examined. Special caution should be paid if the effect is on PTEN activity, because in cells the vast majority of PTEN appears to be monomer and usually only a small percentage of cellular PTEN stably binds to a particular associating factor. As a consequence, the biological effect of such interaction on PTEN function, if any, might be difficult to assess. Furthermore, the biological relevance of affecting a small fraction of cellular PTEN is also hard to picture. There are several possible explanations: could it be that under certain stimulation, an associating factor will be upregulated to bind to significant amount of cellular PTEN? Could it be that a binding protein associates with a small but selective population of PTEN that is dedicated for certain distinct function (for example, at a special cellular compartment)? Or, could a binding protein serve as a scaffold protein that brings PTEN to a specific target (for example, a protein substrate)? Apparently, these questions need further investigation and are important for understanding PTEN function and regulation.
Post-translational modifications PTEN is the target of multiple modes of post-translational modification, including oxidation (Kwon et al., 2004; Ross et al., 2007) , acetylation (Okumura et al., 2006) , phosphorylation and ubiquitination. The mechanisms and biological consequence of these modifications are still obscure. In this review, we will only discuss PTEN phosphorylation (in this section) and ubiquitination (in the following section).
Among all post-translational modification mechanisms, regulation of PTEN by phosphorylation is probably most extensively studied. A cluster of phosphorylation sites (S370, S380, T382, T383 and S385) on its conserved but structurally flexible C-terminal regions was mapped, and casein kinase 2 was shown to be able to phosphorylate these sites (Vazquez et al., 2000; Torres and Pulido, 2001 ). On the basis of these studies and the crystal structure of PTEN (Lee et al., 1999) , an attractive model has been raised: phosphorylation of these sites keeps PTEN in the cytoplasm and thus inactive (in terms of its lipid phosphatase activity); but after dephosphorylation, the C2 domain of PTEN is probably more exposed allowing translocation of PTEN to the plasma membrane to antagonize PI3K-Akt signaling. Intriguingly, the unphosphorylated, active PTEN appears to be more unstable and subject to ubiquitin-mediated proteasomal degradation, providing a feedback regulation mechanism (this model will be discussed again later and in Figure 2 ). Several obvious questions are raised based on this model. For example, this model predicts that dephosphorylation of PTEN is a critical regulatory event, but what is the phosphatase for PTEN, and how is it activated? It was suggested that PTEN is the phosphatase that auto-dephosphorylates itself (Raftopoulou et al., 2004) . If so, then its protein phosphatase activity needs to be activated first to stimulate its lipid phosphatase function. Such sequential execution of the protein and lipid phosphatase activities does not mean PTEN has to go through multiple steps of conformational change: it might be simply achieved by PTEN translocation to plasma membrane (only then the lipid substrate PIP3 becomes available). If indeed PTEN is the protein phosphatase for itself (thus it autoactivates its own PIP3 phosphatase activity), determining the cellular signaling and mechanism that trigger this auto-dephosphorylation activity is essential for understanding both the protein and lipid phosphatase activities of PTEN.
Furthermore, recent evidence showed that PTEN is phosphorylated at additional sites in cells including T366 by GSK3 (Maccario et al., 2007) . It appears T366 phosphorylation can promote PTEN degradation (Maccario et al., 2007) , contrary to the function of the C-terminal cluster phosphorylation.
As the differential phosphorylation/dephosphorylation and other post-translational modification mechanisms individually might only affect a subpopulation of cellular PTEN, we are facing the same question as we do with multiple PTEN associating proteins: how to make sense of the effect of a certain modification if only a small percentage of PTEN is affected (biochemically, it appears that most documented PTEN post-translational modifications cause a decrease in PTEN enzymatic activity in vitro). Again, the same possible explanations for the PTEN-associating proteins can apply here, for example, maybe a subpopulation of cellular PTEN is dedicated to (and sufficient for) a specific biological function, and it is a specific post-translational modification mechanism that defines this subpopulation.
Regulation of PTEN by ubiquitination
Control of PTEN protein stability Many post-translational mechanisms appear to converge on the regulation of PTEN protein stability. For example, as mentioned above, PTEN phosphorylation (Vazquez et al., 2000; Torres and Pulido, 2001; Maccario et al., 2007) and its multiple associating proteins (Tolkacheva et al., 2001; Okahara et al., 2004) have been suggested to regulate its protein stability, presumably via ubiquitin-mediated proteasomal degradation. In addition, deregulation of PTEN protein stability control might be involved in cancer development, as we discussed earlier.
In the ubiquitin-mediated proteasomal degradation pathway, the most important component is usually the enzyme known as ubiquitin ligase or E3, which determines substrate specificity and thus is the major target for regulation (see Hershko and Ciechanover, 1998 for review of the ubiquitin-mediated proteasomal degradation pathway). Recently, our laboratory identified NEDD4-1 (neural precursor expressed, developmentally downregulated 4-1), an HECT domain protein, as the first E3 ubiquitin ligase for PTEN using a biochemical purification approach . NEDD4-1 could potentiate oncogenic Ras-induced cell transformation in a PTEN-dependent manner, suggesting that aberrant upregulation of NEDD4-1 can posttranslationally suppress PTEN in cancers. Furthermore, a reverse correlation of the protein levels of NEDD4-1 with PTEN was also observed in a mouse prostate cancer model and multiple human cancer samples, suggesting that NEDD4-1 is a potential oncogene.
The potential oncogenic role of NEDD4-1 in catalyzing ubiquitin-mediated proteasomal degradation of PTEN is analogous of the role of mdm2 oncogene in mediating degradation of the tumor suppressor p53 (Oren, 2003; Brooks and Gu, 2006 ). Yet, their differences outweigh the similarity, because p53 is by default a quick turnover protein, whereas PTEN is a rather stable Post-translational regulation of PTEN X Wang and X Jiang protein based on studies using cultured cells. p53 is turned over rapidly due to its quick synthesis coupled with quick degradation. This setup ensures that when needed (for example, during DNA damage or other stress), p53 levels can be quickly built up simply by shutting down Mdm2-mediated p53 degradation (Figure 1) (Oren, 2003; Brooks and Gu, 2006) . On the other hand, PTEN is a stable protein, even in cells with NEDD4-1 expression . To explain this phenomenon, we propose a mechanism for the regulation of NEDD4-1-mediated PTEN degradation that is completely opposite to the Mdm2-p53 action: by default, PTEN is stable because the activity of NEDD4-1 toward PTEN is suppressed; but when needed, this blockage will be released (or NEDD4-1 function is stimulated) and thus PTEN degradation is accelerated (Figure 1) . In other words, the function of NEDD4-1 is not to maintain the default turnover of PTEN protein, but rather to attenuate or eliminate PTEN function only upon sensing specific signals.
Then the question becomes, under what physiological conditions, and how, is NEDD4-1 stimulated/de-suppressed to accelerate PTEN degradation (Figure 1) ? Indeed, PTEN degradation was reported to be accelerated under various conditions. For example, zinc, an essential ion for cellular structure and regulation, can induce PTEN degradation in lung epithelial cells (Wu et al., 2003) ; Disruption of cell-cell junctions was also reported to cause PTEN degradation (Subauste et al., 2005) ; further, myocardial ischemia appears to enhance Akt survival signaling partially by enhancing PTEN degradation (Cai and Semenza, 2005; Mocanu and Yellon, 2007) . Therefore, there are multiple important biological instances under which PTEN degradation is accelerated, and whether NEDD4-1 or other PTEN E3 ligases (our unpublished results) are involved in these processes is a readily testable question.
Inappropriate activation of PTEN degradation predisposes to tumorigenesis. This can occur as a consequence of direct mutation of PTEN gene itself and/or alteration of its degradation machinery, such as overexpression or superactivation of NEDD4-1. Indeed, it has been reported that NEDD4-1 expression level is very high in many human cancer cell lines (Anan et al., 1998) , and it has also been documented to be highly overexpressed in a large cohort of human glioma samples (Oncomine database; Sun et al., 2006) . Although the relationship of NEDD4-1 overexpression with PTEN in these gliomas is not clear, the important role of PTEN in gliomas warrants further investigation.
The C-terminal tail of PTEN and ubiquitination
How is the activity of NEDD4-1 toward PTEN turned on to convert PTEN from a stable protein to a degradable protein? A domain study of NEDD4-1-PTEN interaction provided some insights into this question (Wang et al., 2008) . We found that the conserved C-terminal tail (residues 352-403) of PTEN regulates NEDD4-1-catalysed PTEN ubiquitination in an unexpected manner. Although the C-terminal fragment is implicated in the regulation of PTEN degradation, this fragment per se is not required for the interaction or ubiquitination of PTEN by NEDD4-1. Strikingly, deletion of this fragment renders PTEN a stronger binding partner and better ubiquitination substrate for NEDD4-1 than full-length PTEN. Therefore, the C-terminal fragment of PTEN possesses a self-stabilizing capability by antagonizing NEDD4-1-mediated PTEN polyubiquitination and degradation. Consistently, it was reported recently that the C-terminal fragment of PTEN intramolecularly interacts with the C2 domain of PTEN (Odriozola et al., 2007) . We reason that this intramolecular interaction probably masks NEDD4-1 binding with PTEN. Thus, work from our laboratory and others corroborate the notion that C terminus of PTEN is essential for the regulation of both activity and protein stability of PTEN in multiple ways (Figure 2) . By forming intramolecular interactions with the C2 domain, the Cterminal tail may negatively regulate PTEN membranebinding potential, thus exerting an inhibitory effect on the lipid phosphatase activity. The same interaction also protects PTEN from rapid degradation mediated by NEDD4-1, making PTEN a rather stable protein in resting state. It is possible that other events related to Post-translational regulation of PTEN X Wang and X Jiang the C-terminal fragment, such as its phosphorylation and interaction with PDZ domain-containing proteins, affect PTEN stability via modulating the interaction of the C-terminal tail and the C2 domain, and thus the accessibility of NEDD4-1 to PTEN (Figure 2 ). Given the critical role of the C-terminal tail in controlling PTEN degradation, deletion of this fragment results in the rapid degradation of the truncated PTEN protein and subsequent loss of the tumor-suppressive function, even though the C-terminal truncated PTEN is enzymatically intact as the full-length PTEN. Interestingly, many cancer-associated PTEN mutations result in a truncation or frameshift near the end of the C2 domain. Although most of the mutants possess a defective C2 domain rendering them inactive, some mutants do have an intact C2 domain and are thus active enzymatically (Ali et al., 1999; Georgescu et al., 1999 Georgescu et al., , 2000 . These mutants could be selected during tumorigenesis simply because they can be effectively degraded by NEDD4-1-mediated ubiquitination (Figure 2) . Therefore, NEDD4-1 might be a promising therapeutic target for treating cancers bearing such PTEN mutation.
PTEN ubiquitination and Nuclear import
Intriguingly, ubiquitination of PTEN means more than protein degradation. In addition to promoting polyubiquitination and therefore degradation of PTEN, NEDD4-1 can also catalyse monoubiquitination of PTEN, which was shown by Pandolfi's laboratory to promote PTEN nuclear import . Importantly, two Cowden syndrome-derived PTEN mutants, K13E and K289E, are defective in nuclear translocation. As these mutants possess intact enzymatic activity, it is highly likely that their loss of nuclear import might be the cause of the decrease in the tumor-suppressive function. Also, both K13 and K289 are ubiquitination sites of PTEN, and K289 is a major site for NEDD4-1 activity . Interestingly, K289 locates in the flexible/ unstructured but conserved loop region within the C2 domain of PTEN (Lee et al., 1999) . Although lacking experimental evidence, it is tempting to propose that ubiquitination of PTEN at K289 might also disrupt the C2 domain from binding with plasma membrane, and thus inhibit the conventional function of PTEN to antagonize membrane PI3 kinase signaling. figure) , this intramolecular interaction. NEDD4-1 (neural precursor expressed, developmentally downregulated 4-1) can interact and ubiquitinate PTEN efficiently when this intramolecular interaction is released. 'Loop' stands for residues 286-309 of human PTEN, which reside within the C2 domain and contain K289, a major ubiquitination site of NEDD4-1. 'WW' and 'Ub' stand for WW motif and ubiquitin, respectively.
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The function of nuclear PTEN has become a hot topic recently. Evidence confirmed the early observation that nuclear PTEN possesses tumor-suppressive function (Gimm et al., 2000; Whiteman et al., 2002) . Several mechanisms, including antagonizing nuclear Akt signaling (Trotman et al., 2006) and maintaining chromosomal integrity (Shen et al., 2007) , have been proposed. But the picture is far from clear, and it is possible that nuclear PTEN has multiple tumor-suppressive functions. One way to pursue this question is to study the normal physiological function of nuclear PTEN. The observation that PTEN tends to translocate to the nucleus postmitotically or after differentiation in certain tissues strongly suggests a tissue and temporal-specific function(s) of nuclear PTEN (Lachyankar et al., 2000) .
Because nuclear PTEN appears to be unrelated to the level of nuclear PIP3 (Lindsay et al., 2006) , it is likely that it functions by utilizing its protein phosphatase activity or simply by protein-protein interaction. The current advanced proteomic technology makes it feasible to systematically search for nuclear proteins that can serve as the substrates or binding partners of PTEN, although determination of the relevance of the identified proteins might be more difficult. Furthermore, because the majority of PTEN protein is cytosolic and PTEN nuclear translocation is enhanced under specific conditions, PTEN nuclear translocation and, thus, the function of nuclear PTEN have to be regulated. Besides ubiquitination, there are multiple other possible mechanisms that have been proposed to control PTEN nuclear localization (Chung et al., 2005; Minaguchi et al., 2006; Planchon et al., 2008) .
It should be noted that induction of both PTEN proteasomal degradation and nuclear translocation by the same ubiquitin ligase NEDD4-1 is intriguing and somewhat puzzling, because they might lead to distinct and even opposing outcomes. Therefore, the two functions of NEDD4-1 might be differentially regulated in cells. The intrinsic biochemical property of NEDD4-1 makes such differential regulation feasible: enzymatically, NEDD4-1 acts with distributive kinetics toward PTEN, thus monoubiquitination and polyubiquitination of PTEN by NEDD4-1 are essentially two separated steps and might be separately controlled in cells (Wang et al., 2008) . Interestingly, NEDD4-1 acts with processive kinetics toward the C-terminal-truncated PTEN (Wang et al., 2008) , suggesting that a potential mechanism to switch NEDD4-1 from catalyzing PTEN monoubiquitination (thus nuclear import) to polyubiquitination (thus degradation) is to attenuate the intramolecular interaction between the C terminus and the C2 domain of PTEN. Figure 3 Post-translational regulation of PTEN dictates its specific cellular and biological functions. Upon sensing upstream signals, biochemically distinctive subpopulations of PTEN can be generated as a consequence of the induced specific protein-protein interaction, post-translational modification or combination of both. These PTEN subpopulations adopt specific biochemical and cellular properties, and thus are dedicated for diversified and specialized cellular and biological functions. 'Target proximity' indicates that a PTEN subpopulation reaches close proximity to its target, i.e., its protein effector (a protein whose function is regulated by its association with PTEN) or protein substrate. Target proximity can be either achieved by direct interaction or mediated by a scaffold protein that interacts with both PTEN and its protein effector/substrate. 'Subcellular localization' includes translocation of specific PTEN subpopulations to nucleus, plasma membrane, a specialized plasma membrane location or other defined cellular compartments. Arrows among the 'property' circles indicate that change of individual PTEN properties usually influence each other.
Concluding remarks
its various biological functions precisely in a developmental-, tissue-and subcellular-specific manner (Figure 3) . We suggest that in response to a specific biological condition, a subpopulation of cellular PTEN can be regulated by certain post-translational modification mechanisms and/or by binding proteins (it can be a multistep mechanism, for example, first a post-translational modification is induced, which in turn causes PTEN interaction with a binding protein). Such regulation subsequently guides this biochemically distinctive PTEN subpopulation to a specific cellular location or a specific protein substrate/effector, thereby performing a distinct function (Figure 3) . The affected PTEN subpopulation might be only a small fraction of total cellular PTEN, and it is also possible that several discrete PTEN subpopulations simultaneously conduct different functions in the same cells. In light of this hypothesis, some puzzling observations concerning potential PTEN regulation make good sense now. For example, as we have discussed, many identified binding proteins or post-translational modification of PTEN appears to affect only a small fraction of total cellular PTEN, thus their effects, if any, on total cellular PTEN have to be marginal. On the basis of our hypothesis, this phenomenon might simply reflect the fact that PTEN is a multifunctional protein that can exert multiple functions at the same time, and a subpopulation instead of majority of cellular PTEN is guided (and sufficient) to fulfill a certain specific function. In such a model, even the function of PTEN to downregulate PI3K-Akt signaling can be coordinated by a small subpopulation of PTEN (as in the case of NHEFR-PTEN interaction in PDGF signaling (Takahashi et al., 2006) ); and ubiquitin-mediated PTEN degradation can also occur for a small subpopulation of cellular PTEN, leading to a functional outcome in the absence of an obvious change of total cellular PTEN protein level. On the other hand, this model also predicts that many conventional experimental approaches for measuring certain properties of total cellular PTEN or a specific PTEN function (such as decreasing Akt phosphorylation) will fail to reveal its many other functions and regulatory mechanisms.
Finally, the clinical value of targeting PTEN and its regulatory machine should be re-evaluated. The significance of PTEN in cancer biology has been highly appreciated. Recent advances further indicate that deregulation of PTEN function is involved in early stages of tumorigenesis, although its genetic mutation and deletion are mostly identified only in advanced tumors. Therefore, enhancing PTEN function by targeting its regulatory machinery can be an effective cancer therapeutic approach. In addition, we suggest that the potential of PTEN targeting in treating other diseases, especially diabetes, should be reconsidered (Kurlawalla-Martinez et al., 2005; Wijesekara et al., 2005; Rosivatz et al., 2006; Sasaoka et al., 2006; Stiles et al., 2006) . Previously, the enthusiasm of PTEN inhibition for treating diabetes was dampened because of the undesired tumorigenic effect that might be associated with such treatment. However, on the basis of the PTEN subpopulation hypothesis (Figure 3) , it is possible that a specific subpopulation of PTEN instead of total cellular PTEN is directed to specifically antagonize insulin signaling. If so, targeting this specific population of PTEN directly or indirectly via its regulatory machinery could be a promising therapeutic approach without invoking an increase of tumorigenicity. Again, all these potential therapeutic developments require a deeper understanding of PTEN function and regulation.
